Summary
• Bluejay Diagnostics (BJDX) shares rose 5.7% in pre-market trading to $0.7400 following their antibody production milestone announcement.
• The company completed commercial-scale production of polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), critical for inflammatory applications.
• BJDX has a low trading volume and RSI of 19.81, while analysts maintain a “Hold” rating amid recent volatility and significant year-to-date stock decline.
Bluejay Diagnostics, Inc. (BJDX) is experiencing a pre-market rise, currently trading at $0.7400, up 5.7% from its last close of $0.7000. This uptick follows the company’s announcement regarding significant progress in its production capabilities.
Commercial Production Milestone Announced
In a notable update issued on December 29, 2025, Bluejay Diagnostics confirmed the completion of commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6). This biomarker is critical for various inflammatory and critical-care applications, marking a significant advancement in the company’s operational capacity. The announcement underscores Bluejay’s commitment to enhancing its product offerings in a competitive healthcare landscape.
Current Market Performance Metrics
The current session’s trading has seen a volume of 7,720 shares compared to the 10-day average volume of approximately 131,789 shares, indicating a relatively low trading activity thus far. Additionally, BJDX’s RSI stands at a notably low 19.81, reflecting potential oversold conditions as the stock approaches significant historical lows. The company has faced considerable downward pressure over the past year, with a year-to-date performance decline of 85.6%.
Analyst Insights and Market Sentiment
Analysts maintain a “Hold” rating on BJDX, reflecting caution amid the stock’s recent volatility. The company’s last earnings report showed a substantial negative surprise, with actual earnings at -$112.37 against an estimate of -$36, further complicating the stock’s current trading dynamics. Traders will be watching closely to see if this manufacturing update can bolster market sentiment moving forward.
Closing Thoughts
With this latest update reflected in trading, investors will be monitoring how the stock’s volume and momentum develop in the next session. As Bluejay Diagnostics continues to solidify its position in antibody production, the focus will remain on how these developments impact the company’s operational performance and market perception.